| 1 |
|
Completed |
|
Combination Iron Chelation Therapy |
| Conditions: |
|
Iron Overload; Thalassemia |
| Intervention: |
|
Drug: Combination Iron Chelation Therapy |
|
| 2 |
|
Completed |
|
Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency |
| Condition: |
|
Urologic Disease |
| Intervention: |
|
Drug: calcium disodium EDTA (edetate calcium disodium) |
|
| 3 |
|
Active, not recruiting |
|
Penicillamine Chelation for Children With Lead Poisoning |
| Conditions: |
|
Lead Poisoning; Vitamin D Deficiency |
| Interventions: |
|
Device: d-penicillamine; Drug: placebo |
|
| 4 |
|
Active, not recruiting |
|
An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload |
| Condition: |
|
Transfusional Iron Overload in β-Thalassemia |
| Intervention: |
|
Drug: Deferasirox |
|
| 5 |
|
Active, not recruiting |
|
Mercury Chelation to Treat Autism |
| Conditions: |
|
Autism; Asperger’s Disorder; Child Development Disorders, Pervasive |
| Intervention: |
|
Drug: DMSA |
|
| 6 |
|
Active, not recruiting |
|
Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload |
| Condition: |
|
Transfusional Iron Overload in β-Thalassemia Major |
| Intervention: |
|
Drug: Deferasirox |
|
| 7 |
|
Active, not recruiting |
|
Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload |
| Condition: |
|
Transfusional Iron Overload in Patients With Chronic Anemia |
| Intervention: |
|
Drug: Deferasirox |
|
| 8 |
|
Active, not recruiting |
|
Iron-Chelating Therapy and Friedreich Ataxia |
| Condition: |
|
Friedreich Ataxia |
| Intervention: |
|
Drug: Iron chelating intervention |
|
| 9 |
|
Completed |
|
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone |
| Conditions: |
|
Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload |
| Intervention: |
|
Drug: chelation therapy |
|
| 10 |
|
Completed |
|
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload |
| Condition: |
|
Transfusional Iron Overload |
| Intervention: |
|
Drug: Deferasirox |
|
| 11 |
|
Active, not recruiting |
|
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major |
| Condition: |
|
Beta-Thalassemia |
| Intervention: |
|
Drug: deferiprone |
|
| 12 |
|
Completed |
|
CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients |
| Condition: |
|
End Stage Renal Disease |
| Intervention: |
|
|
|
| 13 |
|
Active, not recruiting |
|
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload |
| Condition: |
|
Transfusion-Dependent Iron Overload |
| Intervention: |
|
Drug: Deferasirox |
|
| 14 |
|
Active, not recruiting |
|
Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload |
| Condition: |
|
Transfusion-Dependent Iron Overload |
| Intervention: |
|
Drug: Deferasirox |
|
| 15 |
|
Completed |
|
Efficacy Study in Removing Excess Iron From the Heart |
| Conditions: |
|
Thalassemia Major; Hemosiderosis |
| Interventions: |
|
Drug: Ferriprox (deferiprone); Drug: Desferal (deferoxamine) |
|
| 16 |
|
Active, not recruiting |
|
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients |
| Conditions: |
|
Myelodysplastic Syndrome; Iron Overload |
| Intervention: |
|
Drug: Deferasirox |
|
| 17 |
|
Active, not recruiting |
|
Cardiac Function in Patients With Hereditary Hemochromatosis |
| Condition: |
|
Hemochromatosis |
| Intervention: |
|
|
|
| 18 |
|
Active, not recruiting |
|
A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis |
| Condition: |
|
Sickle Cell Disease |
| Intervention: |
|
Drug: Deferasirox |
|
| 19 |
|
Active, not recruiting |
|
Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis |
| Condition: |
|
Beta-Thalassemia Major |
| Intervention: |
|
Drug: ICL670; deferasirox |
|
| 20 |
|
Completed |
|
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis |
| Condition: |
|
Idiopathic Pulmonary Fibrosis |
| Intervention: |
|
Drug: Tetrathiomolybdate |
|
| 21 |
|
Active, not recruiting |
|
Treatment of Lead-Exposed Children Trial |
| Condition: |
|
Lead Exposure |
| Intervention: |
|
|
|
| 22 |
|
Completed |
|
Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) |
| Conditions: |
|
Beta Thalassemia; Hemoglobinopathy |
| Intervention: |
|
Drug: Hydroxyurea |
|
| 23 |
|
Completed |
|
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia |
| Condition: |
|
Beta Thalassemia |
| Intervention: |
|
Drug: 5-Azacytidine |
|
| 24 |
|
Completed |
|
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis |
| Conditions: |
|
Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload; Hemochromatosis |
| Intervention: |
|
Drug: deferoxamine |
|
| 25 |
|
Completed |
|
Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN) |
| Conditions: |
|
Anemia, Cooley’s; Beta-Thalassemia; Hematologic Diseases; Thalassemia; Osteoporosis; Iron Overload; Hypertension, Pulmonary |
| Interventions: |
|
Drug: Deferoxamine; Drug: Deferiprone; Drug: Arginine; Drug: Sildenafil; Drug: Decitabine |
|
| 26 |
|
Active, not recruiting |
|
Deferoxamine for the Treatment of Hemochromatosis |
| Conditions: |
|
Diabetes Mellitus; Heart Disease; Hemochromatosis; Thalassemia |
| Intervention: |
|
|
|
| 27 |
|
Completed |
|
Monoclonal Antibody Therapy in Treating Patients With Leukemia |
| Conditions: |
|
Lymphoma; Radiation Toxicity |
| Interventions: |
|
Drug: pentetic acid calcium; Drug: yttrium Y 90 daclizumab; Procedure: monoclonal antibody therapy; Procedure: radioimmunotherapy; Procedure: radioprotection |
|
| 28 |
|
Completed |
|
Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions |
| Condition: |
|
Beta-Thalassemia |
| Interventions: |
|
Drug: ICL670; Drug: deferoxamine |
|
| 29 |
|
Completed |
|
Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias |
| Conditions: |
|
Beta-Thalassemia; Myelodysplastic Syndromes; Fanconi Syndrome; Anemia, Diamond-Blackfan; Anemia, Aplastic |
| Intervention: |
|
Drug: Deferasirox |
|
| 30 |
|
Completed |
|
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions |
| Condition: |
|
Anemia, Sickle Cell |
| Interventions: |
|
Drug: ICL670; Drug: deferoxamine |
|
| 31 |
|
Active, not recruiting |
|
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients |
| Conditions: |
|
Sickle Cell Disease; Iron Overload; Hemolytic Anemia |
| Intervention: |
|
Drug: Deferasirox |
|
| 32 |
|
Active, not recruiting |
|
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients |
| Conditions: |
|
Myelodysplastic Syndromes; Iron Overload |
| Intervention: |
|
Drug: deferasirox |
|
| 33 |
|
Completed |
|
Chromium Picolinate for the Treatment of Metabolic Syndrome |
| Conditions: |
|
Metabolic Syndrome X; Prediabetic State; Insulin Resistance; Obesity; Metabolic Diseases |
| Intervention: |
|
Drug: Chromium picolinate |
|
| 34 |
|
Completed |
|
A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis |
| Conditions: |
|
Beta-Thalassemia; Hemosiderosis |
| Intervention: |
|
Drug: deferasirox |
|
| 35 |
|
Active, not recruiting |
|
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload |
| Conditions: |
|
Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia; Myelofibrosis |
| Intervention: |
|
Drug: Deferasirox |
|
| 36 |
|
Completed |
|
Chromium and Insulin Action |
| Condition: |
|
Type 2 Diabetes |
| Intervention: |
|
Drug: Chromium Picolinate |
|
| 37 |
|
Completed |
|
Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM |
| Condition: |
|
Diabetes Mellitus, Type 2 |
| Intervention: |
|
Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg) |
|
| 38 |
|
Completed |
|
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-Dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine |
| Conditions: |
|
Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Hib Disease |
| Interventions: |
|
Biological: Pertussis vaccine; Biological: DTPa-HBV-IPV/Hib |
|
| 39 |
|
Completed |
|
A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM |
| Condition: |
|
Diabetes Mellitus, Type 2 |
| Intervention: |
|
Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg) |
|
| 40 |
|
Completed |
|
Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules |
| Conditions: |
|
Healthy; Infant |
| Intervention: |
|
Biological: DTPa-HBV-IPV/Hib vaccine |
|
| 41 |
|
Completed |
|
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants |
| Conditions: |
|
Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Haemophilus Influenza Type b Disease |
| Intervention: |
|
Biological: DTPa-HBV-IPV/Hib vaccine |
|
| 42 |
|
Active, not recruiting |
|
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine |
| Conditions: |
|
Healthy; Infant |
| Intervention: |
|
Biological: DTPa-HBV-IPV/Hib vaccine |
|
| 43 |
|
Terminated |
|
Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes |
| Condition: |
|
Type 2 Diabetes |
| Intervention: |
|
Drug: Chromium Picolinate |
|
| 44 |
|
Active, not recruiting |
|
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients |
| Condition: |
|
Hemochromatosis |
| Interventions: |
|
Drug: Deferiprone (L1); Drug: Desferrioxamine |
|
| 45 |
|
Active, not recruiting |
|
Iron-Fortified Whole Maize Flour Trial |
| Condition: |
|
Anaemia |
| Intervention: |
|
Drug: NaFeEDTA, Electrolytic Iron |
|
| 46 |
|
Completed |
|
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers |
| Condition: |
|
Healthy |
| Interventions: |
|
Drug: Deferasirox; Drug: Rifampicin |
|
| 47 |
|
Active, not recruiting |
|
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam |
| Condition: |
|
Healthy |
| Intervention: |
|
Drug: Deferasirox |
|
| 48 |
|
Active, not recruiting |
|
Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA |
| Conditions: |
|
Central Nervous System Tumors; Brain Tumors |
| Interventions: |
|
Drug: Gallium-67 Citrate; Drug: In-111 DTPA |
|
| 49 |
|
Completed |
|
Effects of Chromium Picolinate on Food Intake |
| Conditions: |
|
Obesity; Atypical Depression |
| Intervention: |
|
Drug: Chromium Picolinate |
|
| 50 |
|
Completed |
|
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients |
| Condition: |
|
HIV Infections |
| Intervention: |
|
Drug: Ditiocarb sodium |
